Cubist Pharmaceuticals
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections. Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.
Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin).
Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community. Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a β-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.
FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. FORMA’s approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms. FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.